Sonnet BioTherapeutics Holdings, Inc. (SONN) News

Sonnet BioTherapeutics Holdings, Inc. (SONN): $1.56

0.03 (-1.89%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

F

Add SONN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#274 of 334

in industry

Filter SONN News Items

SONN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SONN News Highlights

  • SONN's 30 day story count now stands at 2.
  • Over the past 7 days, the trend for SONN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest SONN News From Around the Web

Below are the latest news stories about SONNET BIOTHERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate SONN as an investment opportunity.

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy

PRINCETON, NJ / ACCESSWIRE / December 21, 2023 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today the publication of extensive preclinical data on ...

Yahoo | December 21, 2023

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update

PRINCETON, NJ / ACCESSWIRE / December 14, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs focused on oncology, announced today its financial ...

Yahoo | December 14, 2023

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview

Following the recent completion of a $4.55 million financing, Sonnet projects cash runway into the calendar year third quarter of 2024The company is focused on its business development initiatives and anticipates being able to provide an update in ...

Yahoo | October 31, 2023

Why Is Sonnet BioTherapeutics (SONN) Stock Down 33% Today?

Sonnet BioTherapeutics stock is dropping on Wednesday after the company revealed the pricing of a public offering for SONN shares.

William White on InvestorPlace | October 25, 2023

EVGO Stock Slips as TD Cowen Downgrades EVgo

EVgo stock is taking a beating on Wednesday as investors in the EV charging company deal with a downgrade and price cut.

William White on InvestorPlace | October 25, 2023

Why Is BioXcel Therapeutics (BTAI) Stock Up 42% Today?

BioXcel Therapeutics stock is rising on Wednesday as investors in BTAI stock react to results from an audit on a clinical trial.

William White on InvestorPlace | October 25, 2023

Why Is InMed Pharmaceuticals (INM) Stock Down 25% Today?

InMed Pharmaceuticals stock is falling on Wednesday after shares of INM underwent a massive rally on Tuesday alongside study results.

William White on InvestorPlace | October 25, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are a hot topic on Wednesday and we're offering all the details that investors need to know about this morning.

William White on InvestorPlace | October 25, 2023

Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering

PRINCETON, NJ / ACCESSWIRE / October 25, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("we," "us," "our," "Sonnet" or the "Company"), a clinical-stage company developing innovative targeted biologic drugs, today announced the pricing ...

Yahoo | October 25, 2023

Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

PRINCETON, NJ / ACCESSWIRE / October 17, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that previously announced interim ...

Yahoo | October 17, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!